Cipla to acquire 100% stake in Inzpera Healthsciences for ₹111 crore

Drug firm Cipla Ltd on Monday (November 3) said it has entered into definitive agreements to acquire a 100% stake in Inzpera Healthsciences Ltd for a total purchase consideration of approximately ₹110.65 crore. Following the transaction, Inzpera will become a wholly owned subsidiary of Cipla.

"...we hereby notify that Cipla Limited (‘the Company’) has entered into definitive agreements to acquire 100% stake in Inzpera Healthsciences Limited (‘Inzpera’). Upon acquisition, Inzpera will become a wholly owned subsidiary of the company," according to a stock exchange filing.

The acquisition, valued at an enterprise value of ₹120 crore, will be completed in cash, subject to closing date adjustments. The deal is expected to conclude within one month from the signing of transaction documents or within a mutually agreed timeline.

Also Read: Cipla Q2 Results: US sales deliver sequential growth; MD & CEO to step down

Cipla said the acquisition is a strategic move aimed at integrating Inzpera’s differentiated portfolio of paediatric pharmaceutical and wellness products with Cipla’s strong distribution network and operational capabilities to drive growth and scalability.

Inzpera Healthsciences, incorporated in 2016, operates in the pharmaceutical industry and focuses on developing, manufacturing, and marketing innovative paediatric and wellness formulations. The company reported revenues of ₹26.75 crore in FY 2024–25, ₹22.05 crore in FY 2023–24, and ₹20.76 crore in FY 2022–23.

The transaction does not fall under related party transactions, and no regulatory approvals are required for its completion. Shares of Cipla Ltd ended at ₹1,511.60, up by ₹9.95, or 0.66%, on the BSE.

Also Read: CNBC-TV18 Exclusive: Umang Vohra says his job at Cipla is complete, clarifies he is not retiring